Education
BPC-157 and TB-500 Evidence & Research Tool
Published Oct 20, 2026
Compare BPC-157 and TB-500 using human evidence, preclinical research, safety data, clinical trials, FDA information and anti-doping rules.
BPC-157 and TB-500 have developed enormous reputations in recovery, sports medicine and peptide communities.
They are frequently associated with claims involving:
- tendon recovery
- ligament healing
- muscle repair
- injury recovery
- wound healing
- inflammation
- faster return to sport
The scientific evidence is much less definitive.
BPC-157 has a substantial preclinical literature and a small amount of preliminary human research.
TB-500 has an even thinner direct evidence base, and much of the research attributed to it online actually involves a different molecule: full-length thymosin beta-4.
This Evidence & Research Tool focuses on one question:
What has actually been demonstrated in humans, what remains preclinical, and what is still unknown?
It does not provide treatment protocols, preparation guidance or instructions for using experimental peptides.
Neither BPC-157 nor TB-500 has established human effectiveness as a standard treatment for musculoskeletal injury.
For BPC-157, published human evidence includes:
- a small retrospective knee-pain study
- a small uncontrolled interstitial-cystitis pilot
- a two-participant intravenous safety report
- older incompletely reported gastrointestinal research discussed by FDA
A randomised Phase 2 trial investigating BPC-157 in acute hamstring injury is also registered.
As of October 2026, the public trial record remains listed as recruiting, with estimated enrolment of 120 participants and no results posted.
View NCT07437547 on ClinicalTrials.gov
TB-500 has substantially less direct human evidence.
A critical distinction is that TB-500 is not the same substance as full-length thymosin beta-4.
FDA's 2026 evaluation described the TB-500 substances it reviewed as related seven-amino-acid fragments of thymosin beta-4.
The agency reported that it had not identified human pharmacokinetic or pharmacodynamic studies specific to TB-500.
A 2026 rat Achilles-tendon study added useful direct preclinical evidence for TB-500.
It remains animal research.
The evidence therefore supports a cautious conclusion:
BPC-157 has limited preliminary human evidence. TB-500-specific human evidence is substantially thinner. Neither has established injury-healing effectiveness in people.
| Research question | BPC-157 | TB-500 |
|---|---|---|
| Direct human research | Yes, but very limited | Extremely limited; FDA identified no direct human pharmacokinetic or pharmacodynamic studies |
| Animal research | Substantial relative to human evidence | Smaller evidence base, including a 2026 rat Achilles-tendon study |
| Laboratory research | Multiple experimental studies | Limited TB-500-specific evidence |
| Established human injury-healing benefit | No | No |
| Long-term human safety established | No | No |
| Component of an FDA-approved drug | No | No |
| Current controlled human research | Phase 2 hamstring study registered as recruiting | No comparable direct human programme identified in FDA's 2026 assessment |
| WADA status | Prohibited under S0 | Thymosin beta-4 and derivatives including TB-500 prohibited under S2.3 |
Not all research answers the same question.
| Evidence type | What it can show | What it cannot establish alone |
|---|---|---|
| Randomised controlled human trial | Stronger evidence of treatment effects and adverse events | May still miss uncommon or long-term risks |
| Small human pilot | Preliminary human signals | Reliable effectiveness or broad safety |
| Observational study | Associations in people | Causation |
| Animal study | Biological effects in a living organism | The same clinical benefit in humans |
| Laboratory study | Mechanisms and cellular responses | Real-world treatment outcomes |
| Anecdote | One person's experience | Population-level effectiveness or safety |
| Marketing claim | How a product is promoted | Scientific evidence |
This distinction is particularly important with BPC-157 and TB-500 because much of their reputation developed from preclinical experiments, mechanistic theories and personal reports rather than large controlled human trials.
What Is BPC-157?
BPC-157 is a synthetic 15-amino-acid peptide.
Experimental research has investigated it in areas including:
- gastrointestinal injury
- tendon models
- ligament injury
- skeletal muscle injury
- wound-related biology
- vascular signalling
- inflammatory pathways
Most of this work has been conducted in animals or laboratory models.
BPC-157 is not a component of an FDA-approved drug in the United States.
Human evidence exists, but it is extremely small relative to the scale of online claims.
A recent systematic review focused specifically on human BPC-157 evidence found only three eligible human studies involving a total of 30 participants.
The authors rated the overall certainty of evidence as very low because of serious methodological limitations.
Read the human-evidence systematic review on PubMed
That gives useful perspective.
BPC-157 is widely discussed.
Its direct human literature remains tiny.
A 2021 publication reported a retrospective study involving people treated for different forms of knee pain.
Seventeen patients were included.
Sixteen were successfully contacted for follow-up.
Twelve had received BPC-157 alone, while four had received BPC-157 together with thymosin beta-4.
Much of the outcome information came from telephone follow-up in which participants described their pain response.
The study had several important limitations:
- no randomisation
- no placebo group
- no blinded assessment
- heterogeneous knee conditions
- no validated functional outcome measure
The reported improvements are therefore an observational human signal.
They do not prove that BPC-157 caused the improvement.
Natural recovery, other treatments, patient selection and expectation effects cannot be excluded.
Read the 2021 knee-pain study on PubMed
A 2024 pilot study involved 12 women aged 39 to 76 with interstitial cystitis who had not responded adequately to previous treatment.
The authors reported improvements in patient-reported symptoms and no adverse events during the study.
But the limitations were substantial.
The study:
- involved only 12 participants
- had no placebo group
- had no blinded comparator
- relied heavily on patient-reported outcomes
- was conducted at a private clinic
These results may justify further controlled research.
They cannot establish effectiveness or a dependable safety profile.
Read the 2024 interstitial-cystitis study on PubMed
A 2025 publication described short-term monitoring in only two adults.
The researchers reported no measurable short-term abnormalities in the laboratory markers examined and no reported adverse effects during the observation period.
But two participants are far too few to establish:
- general human safety
- uncommon adverse effects
- long-term risk
- safety in people with major medical conditions
The study should therefore be understood as a very small preliminary safety report.
It should not be treated as proof that BPC-157 is safe.
FDA's 2026 scientific evaluation also examined older human information involving BPC-157 and ulcerative colitis.
The agency identified substantial limitations in the available evidence.
FDA concluded that the available information was insufficient to establish effectiveness for the proposed ulcerative-colitis use and insufficient to characterise the safety profile adequately.
This distinction matters.
Evidence that a substance has been administered to humans is not the same as evidence that it is an effective medicine.
One of the most important developments in the evidence base is the registered Phase 2 study:
BPC 157 for Acute Hamstring Muscle Strain Repair
ClinicalTrials.gov identifier:
NCT07437547
The registry describes a randomised, double-blind, placebo-controlled trial in people with acute Grade II hamstring muscle strain.
The planned outcomes include clinically relevant measures such as:
- time to unrestricted sport
- MRI-assessed injury changes
- pain
- functional measures
- strength
- safety outcomes
As of October 2026, the study remains listed as recruiting.
Estimated enrolment is 120 participants.
No results are currently posted in the public registry record.
View the current ClinicalTrials.gov record
This is important progress because controlled human research is exactly what the existing BPC-157 evidence lacks.
But the existence of a trial is not evidence that the treatment works.
Until outcome data are reported, it remains ongoing research.
BPC-157 has a much larger animal and laboratory literature than human literature.
Experimental studies have investigated models involving:
- tendon injury
- ligament injury
- skeletal muscle
- gastrointestinal damage
- vascular responses
- wound biology
- inflammatory signalling
A 2025 systematic review of musculoskeletal BPC-157 research identified 36 eligible studies during its search period.
Thirty-five were preclinical.
Only one was classified as clinical.
Read the systematic review on PubMed
That imbalance captures the BPC-157 evidence problem extremely well.
There is considerable experimental biology.
There is very little reliable clinical evidence.
Animal research can justify human trials.
It cannot establish that BPC-157 heals human tendons, ligaments or muscles.
There is not enough high-quality human evidence to describe BPC-157 as having an established safety profile.
FDA has raised concerns involving:
- limited human safety information
- potential immunogenicity
- peptide aggregation
- peptide-related impurities
- active pharmaceutical ingredient characterisation
Read FDA's current peptide compounding safety information
FDA has also reviewed spontaneous adverse-event reports associated with BPC-157 products.
Spontaneous reports can identify safety signals.
They cannot prove causation.
They may contain incomplete information, involve several products at once or lack enough information to determine what caused an event.
FDA's overall conclusion has remained cautious because available human safety information is limited.
Even if future clinical research demonstrates a useful effect for BPC-157, that would not automatically validate every commercial product sold under the same name.
There are at least two separate questions:
What does the BPC-157 molecule do?
And:
What is actually inside this particular finished product?
Experimental peptide products can raise additional concerns involving:
- identity
- purity
- concentration
- impurities
- aggregation
- contamination
- sterility
- storage
- batch consistency
Clinical evidence and manufacturing quality should not be collapsed into one question.
What Is TB-500?
TB-500 is frequently described online as if it were another name for thymosin beta-4.
That is misleading.
FDA's 2026 scientific evaluation distinguishes TB-500 from full-length thymosin beta-4.
The TB-500 substance FDA evaluated is a short, N-acetylated seven-amino-acid fragment corresponding to a region of thymosin beta-4.
Full-length thymosin beta-4 is a different molecule.
This distinction matters because studies involving the full-length parent peptide cannot automatically establish the:
- effectiveness
- pharmacology
- safety
- clinical behaviour
of TB-500.
Related molecules are not necessarily interchangeable.
The direct human evidence is extremely limited.
FDA's 2026 scientific review reported that it had not identified human pharmacokinetic or pharmacodynamic studies specific to the TB-500 free base or acetate substances it evaluated.
FDA also reported that it had not identified a comparable direct human treatment literature for TB-500.
This means claims such as:
"TB-500 has been clinically proven in humans"
require very careful source checking.
Often, the cited paper actually involves full-length thymosin beta-4.
That is a different substance.
Full-length thymosin beta-4 has been investigated in humans.
That literature is scientifically relevant to thymosin beta-4.
It should not automatically be relabelled as TB-500 research.
This distinction affects:
- chemical identity
- pharmacology
- exposure
- safety interpretation
- evidence quality
Whenever a study is used to support a TB-500 claim, check the Methods section and identify the exact molecule researchers administered.
The direct TB-500 evidence base is much smaller than its online reputation suggests.
That changed somewhat in July 2026 when researchers published a study examining BPC-157, TB-500 and their combination in a rat Achilles-tendon model.
Thirty-two male Sprague-Dawley rats were divided into four groups:
- control
- BPC-157
- TB-500
- combined BPC-157 and TB-500
Researchers evaluated biomechanical and tissue-level outcomes after the experimental injury.
The TB-500 group showed a statistically significant increase in maximum load to failure compared with control.
Several histological measures also differed between groups.
Importantly, the researchers reported that combining BPC-157 and TB-500 did not provide additional benefit compared with either compound alone across the study's main comparisons.
This is legitimate direct TB-500 evidence.
It is also animal evidence.
It does not establish that TB-500 improves human tendon healing.
The correct evidence label is:
preclinical.
Human safety remains poorly characterised.
FDA's 2026 evaluation identified a lack of sufficient human exposure information and raised potential concerns involving:
- immunogenicity
- peptide aggregation
- peptide-related impurities
- inadequate product characterisation
View FDA's July 2026 Pharmacy Compounding Advisory Committee materials
This does not prove TB-500 causes a particular adverse effect.
It means there is not enough direct human evidence to estimate its safety reliably.
That distinction matters.
Lack of safety information is not proof of toxicity.
But it is also not evidence of safety.
| Evidence question | BPC-157 | TB-500 |
|---|---|---|
| Direct human evidence | Several very small reports | FDA identified no direct human pharmacokinetic or pharmacodynamic studies |
| Large completed randomised trials | No | No |
| Current controlled clinical research | Recruiting Phase 2 hamstring study | No comparable direct human programme identified |
| Animal evidence | Substantial preclinical literature | Smaller evidence base, including 2026 rat tendon study |
| Human injury-healing effectiveness | Not established | Not established |
| Long-term safety | Not established | Not established |
| FDA-approved medicine containing compound | No | No |
The most defensible conclusion is not that one peptide is "better."
It is that BPC-157 currently has more direct human and preclinical research, while TB-500-specific human evidence remains substantially thinner.
Neither evidence base establishes a standard human treatment for injury recovery.
The two compounds are frequently paired online and are sometimes marketed together under the name "Wolverine stack."
The usual theory is that they may affect different but complementary repair pathways.
That remains a hypothesis.
There is no adequately controlled human clinical evidence establishing that combining BPC-157 and TB-500 improves injury recovery.
The 2026 rat Achilles-tendon experiment is particularly useful because it tested the compounds separately and together.
The combination did not provide an additional benefit over either compound alone across the study's main comparisons.
That animal result does not prove that a combination would fail in humans.
It does show why assumptions about peptide "synergy" need direct testing.
Two experimental treatments do not automatically become more effective when combined.
When several experimental compounds are used together, several problems arise.
Researchers and clinicians may have difficulty determining:
- which substance caused an improvement
- which substance caused an adverse effect
- whether the compounds interact
- whether one changes the metabolism or effects of another
If individual compounds have limited evidence, combining them increases uncertainty rather than eliminating it.
A combination needs evidence for the combination itself.
Regulatory status depends on the exact question being asked.
Approval, pharmacy compounding, research, prescribing, possession and sports eligibility are different regulatory issues.
BPC-157 and TB-500 are not components of FDA-approved drugs in the United States.
In July 2026, FDA presented BPC-157-related and TB-500-related bulk drug substances to its Pharmacy Compounding Advisory Committee as part of the process used to consider substances for the Section 503A Bulks List.
FDA staff recommended against inclusion based on the agency's scientific evaluations.
The advisory committee subsequently voted to recommend BPC-157 and TB-500 for possible inclusion.
Those recommendations are advisory and non-binding.
They are not FDA drug approvals.
They do not establish that either compound is safe or effective for injury recovery.
They also do not by themselves constitute a final amendment to the federal 503A Bulks List.
View FDA's July 2026 meeting materials
The important regulatory distinction is:
A pharmacy-compounding review is not a drug-approval application.
An FDA-approved medicine requires a separate regulatory process involving a specific finished product.
Regulatory wording should remain precise.
Saying:
BPC-157 is not a component of an FDA-approved drug
is different from saying:
every activity involving BPC-157 is illegal.
The same applies to TB-500.
Questions involving:
- clinical research
- laboratory research
- possession
- pharmacy compounding
- prescribing
- importation
can involve different legal frameworks.
Blanket statements should therefore be avoided unless they are supported by the law governing the specific activity.
Competitive athletes face a separate regulatory framework.
The World Anti-Doping Agency's 2026 Prohibited List places BPC-157 within S0, Non-Approved Substances.
Thymosin beta-4 and derivatives such as TB-500 are prohibited under S2.3, Growth Factors and Growth Factor Modulators.
View the 2026 WADA Prohibited List
These prohibitions apply to athletes subject to the World Anti-Doping Code.
Anti-doping prohibition is not the same thing as FDA drug approval or national criminal law.
"Animal Studies Prove BPC-157 Heals Injuries"
They do not.
Animal studies can show changes in experimental healing models.
They cannot establish that the same benefit occurs in humans.
Controlled human studies are needed.
"TB-500 Has Lots of Human Studies"
Check the molecule.
Full-length thymosin beta-4 has human research.
TB-500 is a related fragment.
The evidence should not automatically be transferred from one to the other.
"People Say It Worked, So That Counts as Human Evidence"
Personal experiences matter as observations.
They are not controlled clinical evidence.
Injuries can improve because of:
- time
- rehabilitation
- changes in activity
- surgery
- other treatments
- natural healing
- expectation effects
Without an appropriate comparison group, causation is difficult to establish.
"No Serious Harm Has Been Proven, So It Must Be Safe"
Absence of adequate safety data is not evidence of safety.
Rare adverse effects may require large populations to identify.
Long-term risks require long-term follow-up.
"Research Use Means It Has Been Medically Validated"
No.
A research designation does not establish human safety, treatment effectiveness or medicine approval.
Before accepting a claim, ask:
- What exact molecule was studied?
Was it BPC-157, TB-500, full-length thymosin beta-4 or another derivative?
- Was the research conducted in humans?
Rat, mouse and cellular studies should remain labelled as preclinical.
- Was there a control group?
An uncontrolled case series is a very different level of evidence from a randomised controlled trial.
- What outcome was measured?
A biological marker is not automatically equivalent to reduced pain, restored function or faster return to sport.
- How many people were studied?
Very small studies cannot establish uncommon risks or dependable treatment effects.
- Is the study completed?
A recruiting trial with no results should never be presented as evidence that a treatment works.
- What does the regulator actually say?
Use primary regulatory documents rather than a seller's interpretation.
Is BPC-157 Proven to Heal Tendon Injuries in Humans?
No.
Animal and laboratory research has investigated BPC-157 in tendon and other musculoskeletal models.
Controlled human evidence establishing tendon-healing effectiveness remains lacking.
The current Phase 2 hamstring trial has not reported results.
Does BPC-157 Have Human Research?
Yes.
Published human information includes:
- a small retrospective knee-pain study
- a small interstitial-cystitis pilot
- a two-participant short-term safety study
- older gastrointestinal research discussed by FDA
The evidence is too limited to establish broad effectiveness or long-term safety.
Is the BPC-157 Hamstring Trial Still Recruiting?
As of October 2026, the public ClinicalTrials.gov record for NCT07437547 remains listed as recruiting.
The registry reports estimated enrolment of 120 participants.
No results are posted.
Does TB-500 Have Human Studies?
FDA's 2026 assessment reported that it had not identified direct human pharmacokinetic or pharmacodynamic studies specific to the TB-500 substances it evaluated.
Human research involving full-length thymosin beta-4 should not automatically be treated as TB-500 research.
Is TB-500 the Same as Thymosin Beta-4?
No.
They are related but not identical.
FDA describes the TB-500 material it evaluated as a short seven-amino-acid fragment related to the full-length thymosin beta-4 molecule.
Has TB-500 Been Studied in Animals?
Yes.
A 2026 rat Achilles-tendon study directly examined TB-500, BPC-157 and their combination.
The findings are preclinical.
They do not establish effectiveness in people.
Is BPC-157 FDA Approved?
No.
BPC-157 is not a component of an FDA-approved drug in the United States.
Its consideration within the Section 503A compounding process is a separate regulatory matter and should not be described as FDA drug approval.
Is TB-500 FDA Approved?
No.
TB-500 is not a component of an FDA-approved drug in the United States.
The 2026 advisory committee recommendation concerning possible inclusion on the 503A Bulks List did not constitute FDA drug approval.
Are BPC-157 and TB-500 Prohibited in Sport?
For athletes governed by the World Anti-Doping Code, yes.
BPC-157 is listed under S0.
Thymosin beta-4 and derivatives including TB-500 are listed under S2.3.
Which Has More Evidence?
BPC-157 currently has a larger direct research literature and several very small human reports.
TB-500-specific human evidence remains much thinner.
That does not establish that BPC-157 works.
It only means the evidence bases differ in size and maturity.
BPC-157 and TB-500 have developed online reputations that are much more definitive than the clinical evidence supporting them.
BPC-157 has a substantial preclinical literature and a very small amount of preliminary human research.
The most recent human-focused systematic review found only three eligible studies involving 30 people and rated the certainty of evidence as very low.
A registered Phase 2 hamstring trial may eventually provide much stronger information.
For now, it remains ongoing research with no posted results.
TB-500 has an even larger human evidence gap.
It should not be confused with full-length thymosin beta-4.
FDA's 2026 assessment did not identify direct human pharmacokinetic or pharmacodynamic studies specific to the TB-500 substances it reviewed.
The 2026 rat Achilles-tendon study adds useful preclinical evidence.
It remains animal research.
For both compounds, major safety and effectiveness questions remain unresolved.
The useful questions are therefore not about self-treatment protocols.
They are:
What exact molecule was studied?
Was it studied in humans?
How strong was the study design?
How many people were involved?
What outcome was measured?
What did the researchers actually find?
And what remains unknown?
That is the purpose of this Evidence & Research Tool.
Official FDA meeting page containing the scientific briefing materials for BPC-157-related and TB-500-related bulk drug substances.
Current FDA safety information discussing unresolved concerns involving BPC-157 and peptide-related substances.
Registered Phase 2 randomised, placebo-controlled study. The current public record remains listed as recruiting with estimated enrolment of 120 and no posted results as of October 2026.
Small retrospective human study with substantial methodological limitations.
Small uncontrolled pilot involving 12 women.
Two-participant short-term human safety report.
2026 systematic review identifying three human studies involving 30 participants and rating the certainty of evidence as very low.
Review demonstrating how strongly the published musculoskeletal evidence has historically been weighted toward preclinical research.
2026 direct preclinical study of BPC-157, TB-500 and their combination in a rat Achilles-tendon model.
Official anti-doping source covering BPC-157 and thymosin beta-4 derivatives including TB-500.
Medical Disclaimer
This Evidence & Research Tool is provided for educational and research-information purposes only and is not intended as medical advice, diagnosis or treatment guidance.
BPC-157 and TB-500 are experimental substances without established FDA-approved therapeutic uses in the United States, and important questions about their human safety and effectiveness remain unresolved. Information about experimental peptides should be verified through primary scientific literature, clinical-trial registries and recognised regulatory authorities. Personal medical decisions should be discussed with a qualified healthcare professional.